2022
DOI: 10.7554/elife.78717
|View full text |Cite
|
Sign up to set email alerts
|

Robust group- but limited individual-level (longitudinal) reliability and insights into cross-phases response prediction of conditioned fear

Abstract: Here we follow the call to target measurement reliability as a key prerequisite for individual-level predictions in translational neuroscience by investigating i) longitudinal reliability at the individual and ii) group level, iii) internal consistency and iv) response predictability across experimental phases. 120 individuals performed a fear conditioning paradigm twice six months apart. Analyses of skin conductance responses, fear ratings and BOLD-fMRI with different data transformations and included numbers… Show more

Help me understand this report
View preprint versions

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1
1

Citation Types

0
18
0

Year Published

2022
2022
2024
2024

Publication Types

Select...
4
3

Relationship

2
5

Authors

Journals

citations
Cited by 18 publications
(18 citation statements)
references
References 130 publications
0
18
0
Order By: Relevance
“…In the current study, we use the most common SCR approach in the generalization literature to maximize the compatibility of our work with the prior literature. That said, the field would benefit from more formal analysis of different physiological quantification pipelines in relation to generalization reliability (in line with a move toward multiverse analyses, e.g., Klingelhöfer-Jens et al, 2022;Kuhn et al, 2022). One particularly important avenue for future research in this area are quantification approaches that minimize trial-by-trial variability (e.g., model-based approaches, see Kuhn et al, 2022), and therefore would potentially limit the impact that initial learning trials during the first session have on overall test-retest reliability.…”
Section: Discussionmentioning
confidence: 98%
“…In the current study, we use the most common SCR approach in the generalization literature to maximize the compatibility of our work with the prior literature. That said, the field would benefit from more formal analysis of different physiological quantification pipelines in relation to generalization reliability (in line with a move toward multiverse analyses, e.g., Klingelhöfer-Jens et al, 2022;Kuhn et al, 2022). One particularly important avenue for future research in this area are quantification approaches that minimize trial-by-trial variability (e.g., model-based approaches, see Kuhn et al, 2022), and therefore would potentially limit the impact that initial learning trials during the first session have on overall test-retest reliability.…”
Section: Discussionmentioning
confidence: 98%
“…Few of these steps have been systematically investigated with respect to measurement precision. Recent multiverse-type work suggests that effect sizes and precision derived from different processing and operationalization steps differ substantially despite identical underlying data (Klingelhöfer-Jens et al, 2022;Pineles et al, 2009;Sjouwerman et al, 2016). Furthermore, exclusion of participants due to non-responding in SCRs is based on heterogeneous definitions with potential consequences on measurement reliability and precision (Lonsdorf et al, 2019).…”
Section: Discussionmentioning
confidence: 99%
“…Allen & Yen, 2001) is not straightforward for SCRs. Indeed, larger trial numbers did not generally improve reliability estimates of SCRs (in a learning paradigm; Klingelhöfer-Jens et al, 2022). One interpretation of this result is that increasing precision by aggregation over more trials can get counteracted by sequence effects.…”
Section: Hardware Design and Data Recordingmentioning
confidence: 94%
See 1 more Smart Citation
“…triallevel variance), and n is the number of trials. In practice, this relationship often holds [8,9] though with some exceptions [51,52]. Notably, increasing the number of task trials only benefits reliability if measurement error is random.…”
Section: Decreasing Measurement Noise 321 Increasing Trial Numbersmentioning
confidence: 99%